Clinical Trials Logo

Clinical Trial Summary

Dextromethorphan acts as N-methyl-D-aspartate (NMDA) antagonist. In Treatment resistant schizophrenia(TRS) the efficacy of treatment response by clozapine is only around 40%. Numerous augmentation agent have been tried which includes antipsychotics, anticonvulsants, antidepressants and NMDA antagonist. The NMDA antagonist such as Riluzole and Memantine have shown good efficacy in TRS. Therefore we are evaluating NMDA antagonist, dextromethorphan in TRS. The dextromethorphan or placebo will be administered along with clozapine in TRS patients. The study is randomized double blind placebo controlled group sequential trial.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05944510
Study type Interventional
Source All India Institute of Medical Sciences, Bhubaneswar
Contact RITUPARNA MAITI, M.D.
Phone 9438884191
Email pharm_rituparna@aiimsbhubaneswar.edu.in
Status Recruiting
Phase Phase 4
Start date August 31, 2023
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Completed NCT03807882 - Comparison of Maintenance ECT Versus Clozapine in Treatment-resistant Schizophrenia Phase 4
Not yet recruiting NCT06456983 - Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial N/A
Not yet recruiting NCT06361160 - Reduction of Auditory-Verbal Hallucinations in Schizophrenia Through Cortical Neuromodulation N/A